Effect of Acute Protein Supplementation in Diabetic Patients

December 7, 2025 updated by: JERRY VANLIN, University of Malaya

Effect of House Cricket Preload on Glycemic Response in Type 2 Diabetes Patients

The goal of this trial is to test the effect of house cricket (Acheta domesticus) preload on glycemic response in diabetic patients. The main question[s] it aims to answer are: whether house cricket powder could lower blood glucose spike and stimulate higher insulin response. Participants will consume either house cricket powder, whey protein isolate or placebo which will be mixed with a chicken-flavored soup. Participants fingers will be pricked for up to 2 hours.

Researcher will compare house cricket powder with placebo to see if the glycemic response is better in house cricket supplemented group.

Researcher will compare house cricket powder with whey protein isolate to see if both supplement induce comparable glycemic response.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Participants blood will be collected at 8 time points:

Baseline 20 minutes after pre load 15 minutes after Oral Glucose Tolerance Test (OGTT) 30 minutes after OGTT 45 minutes after OGTT 60 minutes after OGTT 90 minutes after OGTT 120 minutes after OGTT

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Malaysia
    • Sabah
      • Kota Kinabalu, Sabah, Malaysia, 88200
        • Queen Elizabeth Hospital Kota Kinabalu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Suffering from type 2 diabetes mellitus (HbA1c > 6.5%)
  • Consume metformin for at least 6 months

Exclusion Criteria:

  • Consume other type of anti-diabetic drugs
  • Presenting any food allergy
  • Recent surgery or infections that may affect oral glucose tolerance test
  • Consume other drugs that may affect oral glucose tolerance test
  • Not consuming any anti-diabetic drugs
  • Pre-diabetes (HbA1c 5.7 - 6.4%)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
This arm will be given chicken-flavored soup without any supplements before conducting the oral glucose tolerance test
Diagnostic test: Oral Glucose Tolerance test (75g 2-hour)
The participants are required to drink a glucose solution containing 75 g of glucose dissolved in 250 mL of water
Dietary supplement: Placebo
Placebo consists of chicken-flavored soup without any supplement inside
Active Comparator: Whey
This arm will be given chicken-flavored soup containing whey isolate powder before conducting the oral glucose tolerance test
Diagnostic test: Oral Glucose Tolerance test (75g 2-hour)
The participants are required to drink a glucose solution containing 75 g of glucose dissolved in 250 mL of water
Dietary supplement: Whey
Supplemented with whey protein isolate masked with a chicken-flavored soup
Experimental: House Cricket
This arm will be given chicken-flavored soup containing house cricket powder before conducting the oral glucose tolerance test
Diagnostic test: Oral Glucose Tolerance test (75g 2-hour)
The participants are required to drink a glucose solution containing 75 g of glucose dissolved in 250 mL of water
Dietary supplement: House cricket
Supplemented with house cricket powder masked with chicken-flavored soup

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood glucose
Time Frame: 120 minutes
Blood glucose concentration measured using glucometer. Participants fingers are pricked and using capillary tube, a drop of the blood is dripped in a test strip before inserted to a glucometer.
120 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood insulin
Time Frame: 120 minutes
Blood sample is collected through a finger prick. The blood will be centrifuged to obtain the serum. Insulin serum concentration is then measured by using ELISA kits. The blood sample are treated following the kit guideline, and the insulin concentration are measured by comparing the light absorbance against a prepared standard.
120 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Malaya

Investigators

  • Principal Investigator: Ashril Yusof, PhD, University of Malaya

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2025

Primary Completion (Actual)

December 1, 2025

Study Completion (Actual)

December 1, 2025

Study Registration Dates

First Submitted

March 14, 2025

First Submitted That Met QC Criteria

March 14, 2025

First Posted (Actual)

March 17, 2025

Study Record Updates

Last Update Posted (Estimated)

December 9, 2025

Last Update Submitted That Met QC Criteria

December 7, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LPK2203

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe